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TransplantationImmature dendritic cells (iDCs) have been shown to be able to induce peripheral T-cell tolerance through
distinct pathways. Here, we investigated the tolerogenic property of recipient iDCs whose maturation
was arrested by a dominant negative mutant of inhibitor of nuclear factor kappa-B kinase 2 (dnIKK2)
gene. We found that dnIKK2-iDCs presented a typical semi-mature morphology and expressed lower
levels of CD80 and CD86, slightly higher MHC-II than untransfected iDCs. The expression of these mole-
cules had no signiﬁcant change even dnIKK2-iDCs were pulsed by donor antigen. In primary mixed leuko-
cyte reaction (MLR), dnIKK2-iDCs exhibited impaired ability to stimulate allogeneic T-cells, but induced
CD4+CD25 T-cell formation. In co-culture MLR, these CD4+CD25 T-cells suppressed T-cell alloreaction
in an antigen-speciﬁc manner. Besides, CD4+CD25 T-cells inhibited IL-2 and IFN-c release, whereas pro-
moted IL-10 and TGF-b secretion. These data suggested recipient dnIKK2-iDCs could maintain peripheral
tolerance through down-regulating costimulatory molecule expressions and inducing CD4+CD25 T-cell
formation.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Renal transplantation is the optimal mode of replacement ther-
apy in most patients with end-stage renal disease [1–3]. However,
recipients of renal transplants need the lifelong use of immunosup-
pressive medications to prevent graft rejection [4]. The use of
immunosuppressive medications is associated with cumulative
side effects, including increased risks of infection, malignancy, car-
diovascular disease and diabetes [5,6]. Therefore, elimination of
the lifelong need for immunosuppressive drugs and induction ofimmune tolerance remains an elusive and important goal in the
management of renal transplantation.
In the induction of tolerance or immunity, dendritic cells (DCs),
the most potent professional antigen-presenting cells (APCs), play
key roles. After transplantation, DCs present alloantigen to T-cells
through distinct pathways of allorecognition [7,8]. Donor DCs pre-
sent intact donor MHC molecules to T-cells through the direct
pathway; recipient DCs present donor peptides bound on self
(recipient) MHCmolecules to T-cells through the indirect pathway.
Besides, a study has suggested that recipient T-cells can recognize
donor MHCmolecules transferred, intact on the surface of recipient
DCs through the semi-direct pathway [9]. Thus, both donor and
recipient DCs have the potential to induce immunity or tolerance
during transplantation. However, the potential of DCs to induce
immunity or tolerance is largely dependent on the maturation sta-
tus of DC: immature DCs (iDCs) can induce and maintain periph-
eral T-cell tolerance, whereas mature DCs (mDCs) induce T-cells
immunity [10,11]. The tolerogenic properties of iDCs have
prompted considerable interest in exploiting the strategies of
iDC-induced peripheral tolerance for the transplantation. These
strategies include the use of cytokines and growth factors such
as interleukin (IL)-10, transforming growth factor (TGF)-b, and
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overexpression of costimulatory molecules.
Recently, transcription factor nuclear factor (NF)-jB has been
shown to be associated with the maturation and function of DCs
[12,13]. Inhibition of NF-jB or activation of its upstream inhibitor
of NF-jB kinase 2 (IKK2) can block DC antigen presentation both
in vitro and in vivo [13–16]. In keeping with this, a study demon-
strated that treatment of human monocyte-derived iDCs with a
recombinant adenovirus-mediated kinase defective
dominant-negative mutant of IKK2 (dnIKK2) gene inhibited the
allogeneic leukocyte mixed reaction (MLR); and the DCs failed to
increase the expression of MHC II and costimulatory molecules in
response to CD40 engagement [17]. In addition, Tomasoni and his
colleagues used an adenoviral vector encoding dnIKK2 to block
NF-jB activation of rat bone marrow (BM)-derived iDCs and found
that dnIKK2-transfected iDCs were maintained at immature state
[18,19]. These iDCs were capable of prolonging kidney allograft
survival when infused in vivo in rat recipients before transplanta-
tion [18,19]. These ﬁndings suggested that transfection of iDCs
with adenovirus-mediated dnIKK2 gene might be a potent strategy
for the induction of transplantation tolerance.
Of note, as mentioned above, the origin of iDCs has important
impacts on the mode of alloantigen presentation. Donor iDCs not
only are an important source of intact alloantigen for direct recog-
nition pathway, but also indeed provide a source of donor antigen
for the stimulation of T-cells with indirect allospeciﬁcity [20].
Thus, the use of donor iDCs in transplantation has a potential risk
of cross-priming and immunity rather than tolerance [21]. In addi-
tion, donor iDCs, administered 7 days before transplantation to
prevent allograft rejection, is not applicable for clinical cadaveric
renal transplantation. In this study, we transfected recipient
BM-derived iDCs with an adenoviral vector encoding dnIKK2 gene
to arrest the iDC maturation (dnIKK2-iDCs) and determined the
tolerogenic property of dnIKK2-iDCs.2. Materials and methods
2.1. Reagents
Adenovirus vectors were constructed by SinoGenoMax Co., Ltd
(Beijing, China). RPMI 1640, lipopolysaccharides (LPS), dimethyl
sulfoxide (DMSO), cell proliferation and cytotoxicity assay kit
(MTT) were purchased from Sigma (St Louis, MO). Rat lymphocyte
separation medium was purchased from Sino-American
Biotechnology Company (Shanghai, China). Fetal bovine serum
(FBS) was purchased from Nordic Immunological Laboratory
(Tilburg, Netherlands). Magnetic-activated cell sorting (MACS) kit
was purchased from Invitrogen Corporation. Recombinant rat
IL-4 and granulocyte–macrophage colony-stimulating factor
(GM-CSF) were purchased from PeproTech Inc. Phycoerythrin
(PE) labeled anti-rat CD80, CD86, and MHC-II antibodies were pur-
chased from Serotec. IL-2, IL-10, TGF-b, and IFN-c ELISA Kits were
purchased from R&D Systems (Minneapolis, MN, USA). The
replication-deﬁcient adenovirus encoding human IKK2 plasmid,
pACCMVpLpASR(+)-IKK2dn, was a kind gift from Dr. Rain D
Martin (University of Vienna, Vienna, Austria).
pAdxsi-GFP-dnIKK2 and pAdxsi-GFP-0 were constructed by
SinoGenoMax Co., Ltd (Beijing, China).2.2. Animal preparation
A total of 18 male Lewis (LW/CrlBR), Brown Norway (BN/CrlBR),
and Wistar rats (Crl: (WI) BR), weighing 180–200 g at 8–10 weeks
of age, were obtained from Vital River Laboratory Animal
Technology Co. Ltd (Beijing, China). Rats were kept under speciﬁcpathogen-free (SPF) conditions in accordance with the NIH guideli-
nes for the care and use of laboratory animals. Theywere fed a stan-
dard rodent chow andmaintained in a temperature-controlled (23–
25 C) facility with a strict 12-h light/dark cycle, and given free
access to food and water. All procedures involving the rats were
approved by Soochow University Animal Management Committee
and Beijing City Animal Management Committee.
2.3. Generation of recipient BM-derived iDCs
LW (recipient) BM-derived iDCs were prepared as previously
described. Brieﬂy, BM was isolated from recipient tibia and femur
by rinsing the bones with serum-free medium. BM cells were
passed through a 200-mesh sieve to remove the residue. After
being centrifuged at 1500 rpm for 5 min, BM cells were then
re-suspended in serum-free medium. Mononuclear cells were iso-
lated from BM cell suspensions by Ficoll/Hypaque density gradient
centrifugation. Then the cells were cultured in 6-well plates
(Costar, Cambridge, MA) containing RPMI 1640 with 10%
heat-inactivated FBS in the presence or absence of rat GM-CSF
(5 ng/mL) and IL-4 (5 ng/mL) at a density of 2  106/mL per well.
After 2 days of culture, half the mediumwas removed and replaced
with fresh medium containing cytokines. Subsequently, all the
mediums were removed and replaced with fresh medium every
day. At day 5, non-adherent and semi-adherent cells were har-
vested. iDCs were examined by transmission electron microscope
(TEM).
2.4. Generation of dnIKK2-transfected iDCs (dnIKK2-iDCs)
dnIKK2 cDNA was cloned into adenovirus transfer vector
pShuttle-CMV-TEMP (Sinogenomax, Beijing, China). Then,
pShuttle-CMV-TEMP-dnIKK2 was transferred into pAdxsi-GFP
(SinoGenoMax Co., Ltd., Beijing, China) to generate
pAdxsi-GFP-dnIKK2. One day before the iDC infection, 293 T-cells
were cultured in 6-well plates for 24 h in DMEM containing 10%
FBS without antibiotics. When grown to 80–90% conﬂuence, the
293 T-cells were co-transfected with the adeno-vectors containing
pAdxsi-GFP-dnIKK2, pHelper 1.0 and pHelper 2.0 using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA) to produce
adenovirus-dnIKK2 (Adv-dnIKK2). Then the culture supernatants
containing the adenovirus were harvested. The virus particles
(VP) were puriﬁed by two-step cesium chloride density gradient
ultracentrifugation procedure and determined by optical density
(OD, VP/mL = OD260  1.1  1012).
iDCs were cultured in 6-cell plates containing serum-free RPMI
1640 for 4 h. Subsequently, the iDCs were infected with adenovirus
at an MOI of 50 for 3 h. The cultures were then replaced with fresh
medium containing GM-CSF and IL-4 and further cultured for
2 days. After 2 days, the iDCs were collected and re-suspended in
RPMI 1640 containing GM-CSF and IL-4. The infection efﬁciency
was assessed under an inverted ﬂuorescence microscope and the
percentage of cells positive was quantiﬁed using ﬂow cytometry
(FCM). iDCs were also infected with empty adenoviral vector
(Adv0). Untransfected iDCs and the iDCs cultured with LPS
(1 ng/L) were used as control.
2.5. Western blotting analysis for dnIKK2 expression in iDCs
Recipient iDC monolayers were prepared and washed quickly 2
times with cold PBS. Then the iDCs were lysed with a lysis buffer
and protein concentrations were determined by bicinchoninic acid
(BCA) assay kit. Protein samples were mixed with loading buffer
and loaded onto a 10% sodium dodecyl sulfate–polyacrylamide
gel (SDS–PAGE). After electrophoresis, the SDS–PAGE separated
proteins were transferred to a nitrocellulose membrane
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5.0% nonfat milk in PBS and incubated with MA6 anti-ﬂag antibody
in PBS for 1 h. After washing, the membrane was then incubated
with goat anti-mouse IgG conjugated with horseradish peroxidase
in PBS for 1 h. b-Actin was used as a control. Blots were processed
using an ECL Kit (Santa Cruz) and exposed to X-ray ﬁlm.2.6. Preparation of the donor antigen (splenocyte lysates)
Spleen tissues aseptically removed from BN (donor) rats were
washed and minced in Hank’s solution at 0 C to prepare single cell
suspensions. Erythrocytes contaminating in the cell suspensions
were eliminated by adding 5 mL of 0.83% Tris–HCl (pH 7.4) at
37 C and the cells were washed once with Hank’s solution.
Mononuclear cells were separated from the cells by Ficoll–
Hypaque density gradient centrifugation, washed, and
re-suspended in RPMI1640 containing GM-CSF and IL-4 at a cellu-
lar density of 1  108 cells/mL. Then, the re-suspensions were
lysed by 4 freeze (5 min liquid nitrogen)–thaw (10 min in 37 C
bath) cycles. After sonication for 10 min, the lysate was centrifuged
at 300 rpm (10 min, 4 C) and supernatant was recovered. The
lysate was then ﬁltered with a 0.22 lm microporous membrane
and stored at 4 C.2.7. Primary mixed leukocyte reaction (MLR)
Recipient iDCs were incubated for 48 h with donor antigen
(50 lL per 106 iDCs), or as a control, with medium alone, followed
by extensive washing to remove free donor antigen. After being
treated with 25 mg/L mitomycin C for 30 min, the iDCs were
washed three times with RPMI 1640 medium. These
mitomycin-treated iDCs were re-suspended at a concentration of
1  106 cells/mL in medium and used as stimulating cells. Naïve
T-cells (frequency >90%) from the recipient spleen were prepared
and used as responding cells. The concentrations of the responding
cells were also adjusted to 1  106 cells/mL. Stimulating and
responding cells were co-cultured in 96-well plates with a
one-to-ten ratio for 72 h at 37 C in a humidiﬁed atmosphere of
5% CO2. Cell proliferations were determined by MTT assays and
expressed as absorbance values.2.8. Isolation and puriﬁcation of CD4+CD25 T-cells from primary MLR
Cell suspensions were harvested at the end of MLR culture.
CD4+ T-cells were ﬁrst isolated from the suspensions by negative
selection. Brieﬂy, the cell suspensions were centrifuged at
1200 rpm for 10 min, and the cells were re-suspended in 40 lL
MACS buffer/107 cells. Next, the cells were incubated with
biotin-labeled Cocktail (T-cell Isolation Kit II) antibodies and
anti-biotin magnetic beads. After incubating and washing, the cells
were re-suspended in 500 lL MACS buffer/108 cells and loaded
onto MACS separation columns. The columns were then eluted
twice with 1 mL MACS buffer. The efﬂuents from the columns con-
tained the enriched CD4+ T-cells as determined by FCM.
To isolate CD4+CD25 T-cells, the puriﬁed CD4+ T-cell popula-
tions were re-suspended in 90 lL MACS buffer/107 cells.
Subsequently, the cells were incubated with PE-labeled
anti-CD25 antibody and anti-PE magnetic beads. After washing
once, the cells were re-suspended in 500 lL MACS buffer/108 cells
and then isolated by MACS separation column. The CD4+CD25
T-cells (frequency 95.78 ± 1.25%) obtained from the efﬂuents were
washed with RPMI 1640 medium and re-suspended in medium.2.9. dnIKK2-iDC-induced CD4+CD25 T-cells mediated co-culture MLR
Isolated recipient, donor and WI (3rd-party) splenocytes were
treated with 25 mg/L mitomycin C for 30 min and used as stimu-
lating cells. Recipient spleen T-cells (frequency >90%) were isolated
and used as responding cells. The concentrations of both the stim-
ulating cells and responding cells were adjusted to
1  106 cells/mL. Stimulating cells were co-cultured with respond-
ing cells for 72 h in the presence or absence of CD4+CD25 T-cells.
Cell proliferations were determined by MTT as described in the pri-
mary MLR above.2.10. FCM analysis of the surface molecular expressions
iDCs pulsed with or without donor antigen. LPS-cultured DCs
were harvested at the end of culture and washed with PBS. After
being centrifuged at 1500 rpm for 10 min, DCs were
re-suspended at a concentration of 5  106 cells/mL in cold PBS.
100 lL of the DC suspension was added to each speciﬁc antibody
tube. Then, the PE-conjugated anti rat CD80, CD86, and MHC-II
were added to the tubes. As a negative control, PE-conjugated anti
rat IgG was also added to each tube containing DC suspension. The
tubes were incubated at 4 C for 30 min. Finally, the DCs were
washed twice with PBS and re-suspended in 0.5 mL cold PBS.
FCM was used to detect the positive rate of surface molecular
expressions on DCs.2.11. MTT assay for cell proliferation in MLR
Cell proliferation was quantiﬁed by incubating the cells during
the last 4 h of MLR. After removing the supernatant of each well
and washing twice with PBS, 80 lL of RPMI 1640 medium and
20 lL of MTT solution (5 mg/mL in PBS) were added into each well.
The mixture was incubated for another 4 h. Then, the culture
supernatant of each well was removed and 100 lL DMSO was
introduced. After the resultant formazan crystals were completely
dissolved, the absorbance intensity was measured by a microplate
reader (Bio-RAD 680, USA) at 490 nm with a reference wavelength
of 570 nm. Cell proliferation was expressed as absorbance values.2.12. ELISA assay for cytokine levels
IL-2, IL-10, TGF-b and IFN-c levels in the MLR culture super-
natant were measured by cytokine ELISA kits (R&D Systems,
Minneapolis, MN, USA) following the instructions provided by
the supplier.2.13. Statistical analysis
SPSS 13.0 was used for the statistical analyses. All experiments
were repeated at least three times. Data are presented as
mean ± SD. Comparisons were made using one-way ANOVA or t
test. P < 0.05 was considered statistically signiﬁcant.3. Results
3.1. dnIKK2 expressions in iDCs
Western blotting showed a band with relative molecular mass
(Mr) of 87 kDa can be detected in dnIKK2-iDCs. However, no obvi-
ous band was detected in Adv0-iDCs. This demonstrated that the
recombinant dnIKK2 gene could be successfully expressed in rat
iDCs. Results are shown in Fig. 1.
Fig. 1. Western blotting analysis for dnIKK2 expression in iDCs. Samples (15 lg) of
the total cell lysates were separated by 10% sodium dodecyl sulfate–polyacrylamide
gel electrophoresis, transferred to polyvinylidene ﬂuoride membranes. The mem-
brane was incubated with primary antibodies (MA6 anti-ﬂag antibody) and then
incubated with goat anti-mouse IgG conjugated with horseradish peroxidase. b-
Actin was used as a control. Blots were processed using an ECL Kit (Santa Cruz) and
exposed to X-ray ﬁlm.
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even after exposure to allogeneic antigen
Recipient BM-derived mononuclear cells (BMMCs) were cul-
tured with GM-CSF and IL-4 for 5 days to obtain iDCs. iDCs were
transfected with or without Adv-dnIKK2 for another 2 days.
Meanwhile, iDCs were also cultured with LPS for another 2 days
and used as mature DCs.
As shown under TEM (Fig. 2), untransfected iDCs were oval, had
abundant organelles and a smooth surface with a small number of
dendritic protrusions (Fig. 2A), whereas mature DCs showed few
organelles and many dendritic protrusions (Fig. 2C). Interestingly,
dnIKK2-iDCs exhibited a typical semi-mature morphology when
compared to the untransfected iDCs or mature DCs (Fig. 2B).
The DC phenotype was also detected by analysis of surface
molecular expression. FCM analysis showed the expression levels
of CD80, CD86, and MHC-II molecules on mature DCs were signif-
icantly higher than those on untransfected iDCs (P < 0.01).
Transfection with Adv0 in iDCs also caused a signiﬁcant increase
of these surface molecules (P < 0.01). However, the levels of CD80
and CD86 molecules on the dnIKK2-iDCs were not signiﬁcantly
up-regulated, although the expressions of MHC-II mildly increased
(P < 0.05).
Further, we determined the expression changes of these cell
surface molecules after recipient iDCs had been pulsed with donor
antigen. The expression levels of CD80, CD86, and MHC-II on recip-
ient untransfected iDCs were signiﬁcantly up-regulated by stimu-
lation with donor antigen (P < 0.01 or <0.05). Nevertheless, the
increase in expression of these surface molecules was prevented
in recipient dnIKK2-iDCs. The results are given in Table 1.
These ﬁndings suggested recipient dnIKK2-iDCs could retain
their stable immature phenotype even after exposure to allogeneic
antigen.3.3. Recipient dnIKK2-iDCs suppress T-cell proliferation in primary
MLR
To assess T-cell proliferation induced by recipient dnIKK2-iDCs,
a primary MLR was performed. In the primary MLR, recipient iDCs
were pulsed with donor antigen and then co-cultured with naive
recipient naive T-cells. T-cell proliferation was judged by an MTT
assay. As shown in Fig. 3, recipient untransfected iDCs and
Adv0-iDCs induced obvious T-cell proliferation (both P < 0.05).
Nevertheless, recipient dnIKK2-iDCs almost did not cause T-cell
proliferation. Compared with recipient untransfected iDCs and
Adv0-iDCs, in contrast, recipient dnIKK2-iDCs signiﬁcantly
decreased the proliferations of T-cells.
These results indicated recipient dnIKK2-iDCs effectively sup-
pressed T-cell proliferation in the presence of allogeneic antigen.3.4. Recipient dnIKK2-iDCs induce CD4+CD25 T-cell formation
To determine the effects of recipient dnIKK2-iDCs on CD4+
T-cells, we isolated CD4++ T-cells from the primary MLR and
detected the expression of CD25 molecule on these CD+4+ T-cells.
Results are shown in Fig. 4. In the MLR containing recipient
dnIKK2-iDCs against recipient naive T-cells, CD25 expression levels
on CD4+ T-cells were signiﬁcantly lower than those on recipient
untransfected iDCs or Adv0-iDCs against recipient naive T-cells
(both P < 0.01). In CD4+ T-cells from the former, the frequency of
the CD4+CD25+ T-cell population was only 18.6%, the remaining
81.4% consisted mainly of CD4+CD25 T-cells as determined by
FCM analysis.
These ﬁndings demonstrated that recipient dnIKK2-iDCs
induced CD4+CD25 T-cell but not CD4+CD25+ T-cell formation.
3.5. CD4+CD25 T-cells suppress T-cell alloreaction in an antigen-
speciﬁc manner
Since recipient dnIKK2-iDCs induced CD4+CD25 T-cell forma-
tion, we tested the effects of CD4+CD25 T-cells on allogeneic tol-
erance in a co-culture MLR. CD4+CD25 T-cells were isolated and
puriﬁed from primary MLR (1.0–1.5  106 cells/mL). Then naïve
T-cells from the recipient spleen were cultured with
mitomycin-treated recipient, donor or 3rd party splenocytes in
the presence or absence of CD4+CD25 T-cells, respectively. After
72 h of culture, T-cell proliferation was determined by MTT assays.
In the absence of CD4+CD25 T-cells, recipient naïve T-cells
against donor or 3rd party splenocytes had a signiﬁcantly elevated
proliferation as compared with recipient naïve T-cells against syn-
geneic recipient splenocytes (Fig. 5A and B, both P < 0.01). When
various numbers of CD4+CD25 T-cells were added to the cultures
of recipient naïve T-cells against donor splenocytes, the
CD4+CD25 T-cells signiﬁcantly suppressed the proliferation in a
dose-dependent manner. At 1:102 ratio of CD4+CD25 T-cells to
allogeneic splenocytes, the proliferation of T-cells in recipient
naïve T-cells against donor splenocytes were nearly reduced to
that in recipient naïve T-cells against syngeneic recipient spleno-
cytes (Fig. 5A). Similar results were obtained when CD4+CD25
T-cells were added to the cultures of recipient naïve T-cells against
3rd party splenocytes. However, the decrease in T-cell proliferation
against 3rd party splenocytes was not as strong as the inhibition
observed against donor splenocytes (Fig. 5B).
These results suggest that the CD4++CD25 T-cells induced by
recipient dnIKK2-iDCs mediated hyporesponsiveness of T-cells in
an alloantigen-speciﬁc manner.
3.6. CD4+CD25 T-cells affect cytokine production
Further, we detected the cytokine levels in supernatants of the
co-culture MLR to test whether CD4+CD25 T-cells would affect
cytokine production. The results are shown in Table 2. In the
absence of CD4+CD25 T-cells, the levels of IL-2, IL-10, IFN-c and
TGF-b in recipient naïve T-cells against donor or 3rd party spleno-
cytes were signiﬁcantly higher than those in recipient naïve T-cells
against syngeneic recipient splenocytes (all P < 0.01). When
CD4+CD25 T-cells were added, the levels of IL-2 and IFN-c
decreased signiﬁcantly, whereas the levels of IL-10 and TGF-b
increased signiﬁcantly in recipient naïve T-cells against donor
splenocytes (all P < 0.01). However, in recipient naïve T-cells
against 3rd party splenocytes, the cytokine levels had no signiﬁ-
cant difference between the absence and presence of CD4+CD25
T-cells.
These results suggest that CD4+CD25 T-cells suppressed IL-2
and IFN-c release, but promoted IL-10 and TGF-b secretion in an
alloantigen-speciﬁc manner.
Fig. 2. Representative morphology of dendritic cells (DCs) under transmission electron microscope (TEM) at 5000 magniﬁcation. (A) Untransfected immature DCs (iDCs).
Rat bone marrow-derived mononuclear cells were cultured with GM-CSF and IL-4 for 5 days to obtain iDCs. (B) dnIKK2-iDCs. iDCs were transfected with Adv-dnIKK2 and
cultured for another 2 days. (C) Mature DCs. iDCs cultured with LPS for another 2 days.
Table 1
Phenotype analysis of Lewis rat BM-derived iDCs by FCM (% positive cells, n = 3).
CD80 CD86 MHC-II
Unpulsed with donor antigen
Untransfected-iDCs 33.6 ± 2.8 32.3 ± 2.8 34.1 ± 3.5
dnIKK2-iDCs 35.6 ± 4.2 33.7 ± 3.2 46.2 ± 3.7a
Adv0-iDCs 65.5 ± 4.6a 62.6 ± 6.0a 66.4 ± 4.8a
Mature DCs 72.1 ± 5.2a 59.4 ± 4.3a 61.4 ± 4.6a
Pulsed with donor antigen
Untransfected-iDCs + BN Ag 79.3 ± 6.8a 74.8 ± 6.7a 59.8 ± 5.5a
dnIKK2-iDCs + BN Ag 39.1 ± 3.6 35.7 ± 3.1 54.2 ± 5.1a
Adv0-iDCs + BN Ag 79.5 ± 5.6a 75.9 ± 5.4a 58.4 ± 4.3a
BM: bone marrow; iDCs: immature dendritic cells; FCM: ﬂow cytometry; CD:
cluster of differentiation; MHC-II: major histocompatibility complex class II; IKK2:
inhibitor of NF-jB kinase 2; dnIKK2: dominant negative mutant of IKK2; dnIKK2-
iDCs: iDCs transfected with dnIKK2-iDCs gene; Adv0: empty adenoviral vector;
Adv0-iDCs: iDCs transfected with Adv0; BN Ag: Brown Norway rat antigen.
a Comparison with untransfected iDCs, P < 0.05 or 0.01.
Fig. 3. T-cell proliferation induced by recipient iDCs in primary mixed leukocyte
reaction (MLR). Mitomycin-C-treated Lewis rat iDCs pulsed with Brown Norway rat
antigen were cocultured with Lewis rat naive T-cells. T-cell proliferation was
measured by an MTT assay. Results are expressed as absorbance values. The bar
represents the mean ± SD (n = 3). aP < 0.01, vs. iDCs + BN_Ag; bP < 0.01, vs. Adv0-
iDCs + BN_Ag; cP < 0.05, vs. Adv0-iDCs + BN_Ag; dP < 0.01 or 0.05, vs. dnIKK2-
iDCs + BN_Ag; eP < 0.05, vs. dnIKK2-iDCs + BN_Ag.
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In this study, we transfected recipient iDCs with a dnIKK2 gene
to arrest the iDC maturation and investigated the tolerogenicproperty of such dnIKK2-iDCs. Our data showed the recipient
dnIKK2-iDCs presented a typical semi-mature morphology and
expressed low levels of CD80 and CD86 molecules. And the expres-
sion levels of these molecules had no signiﬁcant changes even
though dnIKK2-iDCs were stimulated by alloantigen.
Interestingly, dnIKK2-iDCs pulsed with alloantigen displayed
impaired ability to stimulate allogeneic T-cells, but induced
CD4+CD25 T-cell formation. These CD4+CD25 T-cells suppressed
T-cell alloreaction in an antigen-speciﬁc manner. In addition, we
found the CD4+CD25 T-cells inhibited IL-2 and IFN-c release,
whereas promoted IL-10 and TGF-b secretion in response to allo-
geneic stimuli.
It is widely assumed that the maturation/activation state of DCs
is fundamental in the induction of tolerance [22,23]. DC matura-
tion is a process associated with loss of antigen-capturing ability
but increase of capacity for T-cell activation. One of the phenotypic
hallmarks of DC maturation is a dramatic increase in surface
MHC-II and costimulatory molecules, while iDCs express only
small quantities of MHC-II but no or very low levels of costimula-
tory molecules [22]. The full activation of T-cells requires at least
two signals, i.e. antigen recognition (ﬁrst signal) and costimulation
(second signal). They are respectively mediated via peptide-MHC
complex (ﬁrst signal) and costimulatory molecules (second signal)
on the APC surface [24,25]. Antigen presentation in the absence of
costimulation can lead to clonal T-cell anergy [26], thereby main-
taining T-cell tolerance. However, the induction of peripheral toler-
ance may vary according to the peripheral environment. Some
studies suggested that peripheral tolerance was induced by iDCs
lacking expression of MHC-II and costimulatory molecules
[10,11]. Other groups reported that tolerance could also be induced
by DCs expressing high levels of MHC-II but relatively low levels of
costimulatory molecules [27,28]. In the present study, recipient
dnIKK2-iDCs showed a typical semi-mature morphology and
expressed low levels of costimulatory molecules CD80 and CD86
as untransfected iDCs. Besides, the expression levels of these cos-
timulatory molecules were not signiﬁcantly up-regulated even
when recipient dnKK2-iDCs were pulsed with donor antigen.
These results suggested recipient dnIKK2-iDCs could retain their
stable immature phenotype. Nevertheless, our data revealed the
expressions of MCH-II molecules on the recipient dnIKK2-iDCs
pulsed with donor antigen were maintained at a relatively high
level. Despite of this, however, our primary MLR showed the recip-
ient dnIKK2-iDCs pulsed with donor antigen induced very low
T-cell proliferative responses. These are similar to the cases of
DCs treated with vitamin D3 [27] and NF-jB decoy ODN [28].
Hence, the discordant regulation of MHC-II and costimulatory
molecule expression may be because the induction and mainte-
nance of tolerance require the presentation of antigen in the con-
text of MHC molecules and the absence of costimulation [26,29].
Fig. 4. The effects of recipient iDCs on CD25 expression in CD4+ T-cells. CD4+ T-cells were ﬁrst isolated and puriﬁed from the primary mixed leukocyte reaction (MLR) by
negative selection. Then, the puriﬁed CD4+ T-cells were stained with PE-labeled anti-CD25 antibody. Negative controls were performed with PE-conjugated anti rat IgG. (A)
One representative experiment of three is shown. (B) The positive rate of CD25 molecular expression on CD4+ T-cells was quantiﬁed by ﬂow cytometry. The bar represents the
mean ± SD (n = 3). aP < 0.01, vs. iDCs; bP < 0.01, vs. Adv0-iDCs.
Fig. 5. CD4+CD25 T-cells mediated co-culture mixed leukocyte reaction (MLR). CD4+CD25 T-cells were isolated and puriﬁed from primary MLR (1.0–1.5  106 cells/mL). (A)
mitomycin-treated BN (donor) splenocytes were incubated with LW (recipient) spleen T-cells for 72 h in the presence or absence of the puriﬁed CD4+CD25 T-cells. (B)
mitomycin-treated WI (third-party) splenocytes were incubated with LW (recipient) spleen T-cells for 72 h in the presence or absence of the puriﬁed CD4+CD25 T-cells. As a
control, mitomycin-treated LW (recipient) splenocytes were incubated with LW (recipient) spleen T-cells for 72 h. T-cell proliferation was determined by MTT assays. Results
are expressed as absorbance values. The bar represents the mean ± SD (n = 3). aP < 0.01, vs. LW–LW; bP < 0.01, vs. LW–BN + CD4+CD25 T-cells (1:102); cP < 0.05, vs. LW–
BN + CD4+CD25 T-cells (1:104); dP < 0.01, vs. LW–LW; eP < 0.05, vs. LW–WI + CD4+CD25 T-cells (1:102).
Table 2
Cytokine analysis of co-culture MLR supernatants in the absence or presence of CD4+CD25 T-cells (pg/mL, x ± s, n = 3).
MLR IL-2 IL-10 IFN-c TGF-b
LW–LW
Absence <10a,b <10a,b <10a,b <10a,b
Presence – – – –
LW–BN
Absence 154.43 ± 10.87c 20.26 ± 1.33c 298.21 ± 18.49c 50.53 ± 4.53c
Presence 27.26 ± 4.35 52.42 ± 4.72 65.20 ± 5.68 266.47 ± 14.66
LW–WI
Absence 157.06 ± 12.91 20.75 ± 1.38 313.35 ± 18.70 56.29 ± 5.56
Presence 159.15 ± 11.98 19.70 ± 2.07 311.78 ± 24.26 52.6 ± 5.48
MLR: mixed leukocyte reaction; LW–LW: mitomycin C-treated Lewis rat (recipient) splenocytes against Lewis rat (recipient) spleen T-cells; LW–BN: mitomycin C-treated
Lewis rat (recipient) splenocytes against Brown Norway rat (donor) spleen T-cells; LW–WI: mitomycin C-treated Lewis rat (third-party) splenocytes against Wistar rat (WI)
spleen T-cells.
a Comparison with LW–BN in the absence of CD4+CD25 T-cells, P < 0.01.
b Comparison with LW–WI in the absence of CD4+CD25 T-cells, P < 0.01.
c Comparison with LW–BN in the presence of CD4+CD25 T-cells, P < 0.01.
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and have been considered as tolerogenic DCs [30,31], a growing
body of evidence indicates that iDCs can actively maintain periph-
eral tolerance by induction and/or stimulation of Tregs [30,32,33].
Tregs, formerly known as suppressor T-cells, may be classiﬁed into
naturally occurring CD4+CD25+ Tregs (nTregs) and inducible Tregs
(iTregs). One of the best-characterized and unique subsets ofnTregs is CD4+CD25+ nTreg. nTregs are genetically controlled and
exert suppressive effects via cell contact by membrane-bound
molecules [34,35]. iTregs include Type 1 regulatory T-cells (Tr1),
T helper 3 (Th3), etc. They are generated from peripheral CD4+
T-cells induced with IL-10, TGF-b, or iDCs. iTregs have a
cytokine-dependent mechanism of action in the periphery
[36,37]. In addition, evidences indicated the presence of
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vert CD4+CD25 T-cells into CD4+CD25+ Tregs with suppressive
capacity [38]. To gain insight into the mechanism by which recip-
ient dnIKK2-iDCs induce peripheral tolerance, we determined
whether recipient dnIKK2-iDCs would expand CD4+CD25+ Tregs
or convert CD4+CD25 T-cells into CD4+CD25+ Tregs and the effects
of these Tregs on T-cell alloreaction.
Our data showed the recipient dnIKK2-iDCs pulsed with donor
antigen signiﬁcantly suppressed the expression levels of CD25 on
CD4++ T-cells when compared with the recipient untransfected
iDCs or Adv0-transfected iDCs. This suggested CD4+CD25+ Tregs
could not be expanded or converted from naive CD4+CD25
T-cells. This ﬁnding was not consistent with the previous study
[38]. The reasons for these discrepancies are not very clear.
However, we believe dnIKK2-iDCs suppress CD4+CD25+ T-cell for-
mation under the inﬂuence of a speciﬁc microenvironment, caus-
ing a relative expansion of the CD4+CD25 T-cells. An important
point is the cells of the immune systemmay secrete various cytoki-
nes by antigen-speciﬁc and non-antigen speciﬁc stimuli in immune
responses. Evidences have shown that CD25 expression levels are
regulated by cytokines such as IL-2 [39], although it is not known
whether these cytokines act as peripheral differentiation factors or
expansion factors. Interestingly, our co-culture MLR revealed that
dnIKK2-iDC-induced CD4+CD25 T-cells potently suppressed the
alloreaction of T-cells. Moreover, contrary to CD4+CD25+ nTreg
cells showing no or only marginal rates of cytokine production
[40], these CD4+CD25 T-cells signiﬁcantly suppressed the release
of IL-2 and IFN-c whereas promoted the secretion of IL-10 and
TGF-b. Since iTregs exert their suppressor activity mainly by pro-
ducing IL-10 and TGF-b [36,41], our CD4+CD25 T-cells might have
the functional characteristics of iTregs but not CD4+CD25+ nTregs.
Of note, a subset of CD4+ regulatory cells Tr1 also shares these
characteristics and can be induced by iDCs in the presence of
IL-10 [42]. However, although Tr1 must encounter the antigen
toward which they are speciﬁc to exert their suppressive function,
the activated Tr1 suppress the proliferation of other T-cells in an
antigen non-speciﬁc manner [43]. This is different from our
CD4+CD25 T-cells, as they have an antigen-speciﬁc manner sup-
pressive effect on the T-cell alloreaction. Admittedly, the response
of recipient T-cells to third party antigen was also somewhat sup-
pressed by CD4+CD25 T-cells, indicating there was antigen
non-speciﬁc suppression. This may be related to the fact that
CD4+CD25 T-cells are stimulated by third-party APCs to secrete
cytokines. Mediated via these cytokines, antigen-speciﬁc
CD4+CD25 T-cells suppressed the response of recipient T-cells to
third party antigen by bystander suppression and/or linked sup-
pression. In fact, some studies have suggested that both
CD4+CD25+ and CD4+CD25 subsets are able to suppress immune
response and mediate dominant transplantation tolerance
[44,45]. Therefore, it is reasonable that recipient dnIKK2-iDCs
maintain peripheral tolerance mediated by CD4+CD25 Treg.
Several limitations of the current study need to be addressed.
Current dogma has focused on the importance of Foxp3+ Tregs in
transplant models, and indeed in autoimmunity/self-tolerance.
Foxp3 is a crucial transcriptional factor that is exclusively
expressed in Tregs and has been described as a master gene for
the development and function of Tregs. FoxP3 is expressed mainly
by CD4+CD25+ Tregs [46], but it was also expressed by CD4+CD25
T-cells with regulatory activity [19,46]. Unfortunately, because of
the limitations in our original research design and budget con-
straint, we failed to examine the level of Foxp3 expression in our
CD4+CD25 T-cell subsets. Thus we do not know whether FoxP3
is expressed by recipient dnIKK2-iDC-induced CD4+CD25 T-cells.
In addition, we should have looked at the effect of other inﬂamma-
tory agents (such as IL-6, IL-17), the balance between Tregs and
Th17, etc. Therefore, further study is required.5. Conclusion
The evidences provided by the present study show that the
maturation of recipient-derived iDCs is signiﬁcantly arrested by
dnIKK2, which induces alloantigen-speciﬁc T-cell hyporesponsive-
ness. The mechanism(s) responsible may, at least, involve the deﬁ-
cient expression levels of costimulatory molecules and the
CD4+CD25 Tregs. This suggests that recipient dnIKK2-iDCs may
potentially be feasible to use in the induction of clinical transplan-
tation tolerance.
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